Globus Medical Inc banner

Globus Medical Inc
NYSE:GMED

Watchlist Manager
Globus Medical Inc Logo
Globus Medical Inc
NYSE:GMED
Watchlist
Price: 80.39 USD -0.16% Market Closed
Market Cap: $10.9B

Wall St Price Targets

GMED Price Targets Summary
Globus Medical Inc

Wall Street analysts forecast GMED stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GMED is 111.35 USD with a low forecast of 87.87 USD and a high forecast of 128.1 USD.

Lowest Forecast
Price Target
87.87 USD
9% Upside
Average Forecast
Price Target
111.35 USD
39% Upside
Highest Forecast
Price Target
128.1 USD
59% Upside
Globus Medical Inc Competitors:
Price Targets
9688
Zai Lab Ltd
62% Upside
FDMT
4D Molecular Therapeutics Inc
226% Upside
PXS
Pyxis Tankers Inc
121% Upside

Revenue
Forecast

17% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
17% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 3 years is 8%.

Gross Profit
Forecast

15% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
15% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 3 years is 10%.

Operating Income
Forecast

13% / Year
Past Growth
23% / Year
Estimated Growth
Estimates Accuracy
-27%
Average Miss
13% / Year
Past Growth
23% / Year
Estimated Growth
Estimates Accuracy
-27%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 23%.

Pre-Tax Income
Forecast

14% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-31%
Average Miss
14% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-31%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 14%. The projected CAGR for the next 3 years is 19%.

Net Income
Forecast

17% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-33%
Average Miss
17% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-33%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 17%. The projected CAGR for the next 3 years is 14%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is GMED's stock price target?
Price Target
111.35 USD

According to Wall Street analysts, the average 1-year price target for GMED is 111.35 USD with a low forecast of 87.87 USD and a high forecast of 128.1 USD.

What is the Revenue forecast for Globus Medical Inc?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 3 years is 8%.

What is the Gross Profit forecast for Globus Medical Inc?
Projected CAGR
10%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 3 years is 10%.

What is the Operating Income forecast for Globus Medical Inc?
Projected CAGR
23%

Over the last 13 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 23%.

What is the Pre-Tax Income forecast for Globus Medical Inc?
Projected CAGR
19%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 14%. The projected CAGR for the next 3 years is 19%.

What is the Net Income forecast for Globus Medical Inc?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Net Income has been 17%. The projected CAGR for the next 3 years is 14%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett